#ASCO13 #ASH13 #SABCS13 #GI14 #GU14
174 views | +0 today
Follow
Your new post is loading...
Your new post is loading...
Scooped by oncdoc7
Scoop.it!

ASH 2013: Critical Issues Need Answers - Providing Best Options for Myeloma Treatment in 2013 - YouTube

Critical Issues Need Answers: Providing Best Options for Myeloma Treatment in 2013 Originally Aired December 6, 2013 Ernest N. Morial Convention Center New O...
oncdoc7's insight:

Brian Durie, MD

more...
No comment yet.
Scooped by oncdoc7
Scoop.it!

Critical insights on leukaemia and lymphoma from ASH 2013 - YouTube

Prof Robin Foa, Dr Simon Rule and Dr Clemens Wendtner discuss the main highlights presented from the ASH 2013 meeting. The participants discuss recent treatm...
more...
No comment yet.
Scooped by oncdoc7
Scoop.it!

Hedgehog Inhibitor Regimen Active in Advanced Pancreatic Cancer

Hedgehog Inhibitor Regimen Active in Advanced Pancreatic Cancer | #ASCO13 #ASH13 #SABCS13 #GI14 #GU14 | Scoop.it
Add-on treatment with the hedgehog pathway inhibitor vismodegib demonstrated encouraging activity in patients with untreated metastatic pancreatic ductal adenocarcinoma.
oncdoc7's insight:

Vismodegib added to Gemzar Abraxane, 10 mth OS

more...
No comment yet.
Scooped by oncdoc7
Scoop.it!

Ramucirumab/Paclitaxel Combination Shows OS Benefit in Metastatic Gastric Cancer

Ramucirumab/Paclitaxel Combination Shows OS Benefit in Metastatic Gastric Cancer | #ASCO13 #ASH13 #SABCS13 #GI14 #GU14 | Scoop.it
The combination of ramucirumab and paclitaxel resulted in a significant prolongation in survival and gains in quality of life when compared to paclitaxel alone for the second-line treatment of patients with metastatic gastric cancer.
more...
No comment yet.
Scooped by oncdoc7
Scoop.it!

High Response Rates Observed With CAPTEM in Chemo-Resistant Neuroendocrine Tumors

High Response Rates Observed With CAPTEM in Chemo-Resistant Neuroendocrine Tumors | #ASCO13 #ASH13 #SABCS13 #GI14 #GU14 | Scoop.it
Data from an interim analysis of an ongoing phase II study suggest that patients with carcinoid and pituitary NETs, who have been traditionally chemo-resistant, may obtain “extraordinary responses” with capecitabine and temozolomide.
more...
No comment yet.
Scooped by oncdoc7
Scoop.it!

▶ Comment Prof. Dr. med. Carsten Bokemeyer, Hamburg - YouTube

2014 Gastrointestinal Cancers Symposium (ASCO-GI); Comment Prof. Dr. med. Carsten Bokemeyer, Hamburg, extended analysis of KRAS/NRAS mutations, consquences f...
more...
No comment yet.
Scooped by oncdoc7
Scoop.it!

Second-Line Trastuzumab Active in HER2-positive Advanced/Recurrent Gastric Cancer - Chemotherapy Advisor

Second-Line Trastuzumab Active in HER2-positive Advanced/Recurrent Gastric Cancer - Chemotherapy Advisor | #ASCO13 #ASH13 #SABCS13 #GI14 #GU14 | Scoop.it
Second-line treatment with paclitaxel/trastuzumab showed promising activity in trastuzumab-naïve patients with HER2-positive gastric cancer.
more...
No comment yet.
Scooped by oncdoc7
Scoop.it!

Nab-Paclitaxel/Gemcitabine Sustains OS in Metastatic Pancreatic Adenocarcinoma - Chemotherapy Advisor

Nab-Paclitaxel/Gemcitabine Sustains OS in Metastatic Pancreatic Adenocarcinoma - Chemotherapy Advisor | #ASCO13 #ASH13 #SABCS13 #GI14 #GU14 | Scoop.it
Nab-paclitaxel plus gemcitabine sustained overall survival rates compared with gemcitabine alone in patients with metastatic pancreatic adenocarcinoma.
more...
No comment yet.
Scooped by oncdoc7
Scoop.it!

Final stage II results of the CLL11 trial. Final stage II results of the CLL11 trial. ecancer.tv - Essential viewing for oncologists

Final stage II results of the CLL11 trial. Final stage II results of the CLL11 trial. ecancer.tv - Essential viewing for oncologists | #ASCO13 #ASH13 #SABCS13 #GI14 #GU14 | Scoop.it
oncdoc7's insight:

Obinutuzumab plus Chlorambucil superior to Rituxan plus Chlorambucil in elderly. Valentin Goede, MD. video.

more...
No comment yet.
Scooped by oncdoc7
Scoop.it!

Twitter / clearasblood: Summary slides from Klampfl ...

Twitter / clearasblood: Summary slides from Klampfl ... | #ASCO13 #ASH13 #SABCS13 #GI14 #GU14 | Scoop.it
oncdoc7's insight:

CALR mutation seen in 70-80% of JAK2/MPL negative MPN. Nangalia. LBA#2. ASH13

more...
No comment yet.
Scooped by oncdoc7
Scoop.it!

Twitter / mtmdphd: #ASH13 - MPN - ET Pt Clinical ...

Twitter / mtmdphd: #ASH13 - MPN - ET Pt Clinical ... | #ASCO13 #ASH13 #SABCS13 #GI14 #GU14 | Scoop.it
oncdoc7's insight:

CALR - Careticulin mutation,  mutually exclusive with JAK2.  found in 70% of ET and 50% MF.  ASH 13

more...
No comment yet.
Scooped by oncdoc7
Scoop.it!

OBR Peer Reviews - Robert Figlin, MD and Nicholas Vogelzang, MD - ASCO GU 2014 - YouTube

Robert Figlin, MD and Nicholas Vogelzang, MD discuss effects of data released at the ASCO 2014 GU Symposium. FOCUS ON: PROSTATE CANCER. http://www.obroncolog...
more...
No comment yet.
Scooped by oncdoc7
Scoop.it!

Dr. Link on Algenpantucel-L for Pancreatic Cancer

Charles J. Link, Jr, MD, from the Cancer Center of Iowa and NewLink Genetics, discusses the phase II trial of algenpantucel-L for pancreatic cancer.
more...
No comment yet.
Scooped by oncdoc7
Scoop.it!

Vaccine Combination Demonstrates Benefit in Metastatic Pancreatic Cancer

Vaccine Combination Demonstrates Benefit in Metastatic Pancreatic Cancer | #ASCO13 #ASH13 #SABCS13 #GI14 #GU14 | Scoop.it
According to the results of a phase II study, the combination of two specific anti-cancer vaccines, rather than the administration of one as monotherapy, doubles the 1-year survival probability in patients with metastatic pancreatic ductal...
more...
No comment yet.
Scooped by oncdoc7
Scoop.it!

Neoadjuvant Capecitabine Considered a New Standard of Care in Rectal Cancer

Neoadjuvant Capecitabine Considered a New Standard of Care in Rectal Cancer | #ASCO13 #ASH13 #SABCS13 #GI14 #GU14 | Scoop.it
Single-agent neoadjuvant capecitabine combined with radiation therapy demonstrated similar outcomes as previously established standards of care for patients with stage II or stage III rectal cancer.
more...
No comment yet.
Scooped by oncdoc7
Scoop.it!

Cetuximab Does Not Improve FOLFOX4 Outcomes for CRC with RAS Mutations - Chemotherapy Advisor

Cetuximab Does Not Improve FOLFOX4 Outcomes for CRC with RAS Mutations - Chemotherapy Advisor | #ASCO13 #ASH13 #SABCS13 #GI14 #GU14 | Scoop.it
Cetuximab should not be added to first-line FOLFOX4 for patients whose mCRC harbors RAS mutations.
oncdoc7's insight:

60% rr with Erbitux addition in WT KRAS vs 30%  in Mutation KRAS. 

more...
No comment yet.
Scooped by oncdoc7
Scoop.it!

NeoALTTO trial indicates breast cancer patients who had pathologic complete response had improved event-free and overall survival. NeoALTTO trial indicates breast cancer patients who had pathologic...

NeoALTTO trial indicates breast cancer patients who had pathologic complete response had improved event-free and overall survival. NeoALTTO trial indicates breast cancer patients who had pathologic... | #ASCO13 #ASH13 #SABCS13 #GI14 #GU14 | Scoop.it
more...
No comment yet.
Scooped by oncdoc7
Scoop.it!

Twitter / mtmdphd: #ASH13 - GF1B Gray Plt Synd ...

Twitter / mtmdphd: #ASH13 - GF1B Gray Plt Synd ... | #ASCO13 #ASH13 #SABCS13 #GI14 #GU14 | Scoop.it
oncdoc7's insight:

Growth Factor Independent 1B mutation is seen in Gray Platelet syndrome (alpha granule deficiency).  LBA#3 ASH13

more...
No comment yet.